Search Tag: Hologic
Breast-tomosynthesis-a-positive-investment
2013 21 Mar
Breast tomosynthesis has created a lot of interest within the women’s imaging community. While the clinical benefits are becoming more apparent, the reimbursements in the U.S. are inconsistent, and it is expensive to adopt this technology. Providers want to know: Is it worth the investment? Is a positive return on investment (ROI) possible? Hologic...Read more
Benefits-of-hologic-s-breast-tomosynthesis-supported-in-published-italian-study
2013 09 May
Hologic has announced the publication of the final results of a large-scale prospective study comparing breast cancer screening using Hologic's 2D mammography plus tomosynthesis (Breast Tomosynthesis) with conventional 2D mammography published online in advance of print by The Lancet Oncology. The study, "Integration of 3D digital mammography with...Read more
Hologic-q2-2013-results
2013 17 May
Hologic has announced its results for the second fiscal quarter ended March 30, 2013. Highlights Include: Financial: Revenues of $612.7 million, net of a $(6.4) million adjustment related to contingent revenue earned and received under Gen‐Probe Incorporated's (Gen‐Probe) collaboration agreement with Novartis. Non‐GAAP adjusted revenues...Read more
Hologic-gets-fda-approval-for-new-low-dose-breast-tomosynthesis-solution
2013 24 May
Hologic has announced US Food and Drug Administration approval of its new C-View 2D imaging software. C-View 2D images may now be used in place of the conventional 2D exposure previously required as part of a Hologic 3D mammography (breast tomosynthesis) screening exam. C-View images are generated from the 3D tomosynthesis data acquired during...Read more
Hologic-s-breast-tomosynthesis-reduces-recall-rates-and-improves-cancer-detection-u-s-study
2013 24 May
Hologic has announced that the first large-scale observational study in a U.S. clinical practice comparing breast cancer screening with Hologic's 3D mammography technology (breast tomosynthesis) with conventional 2D mammography alone showed a significant reduction in recall rates and a sizeable increase in cancer detection, particularly invasive cancer,...Read more
In-breast-cancer-detection-the-evidence-points-to-tomosynthesis
2013 17 Sep
Growing number of peer-reviewed clinical publications document significant advantages of H ologic® tomosynthesis; Now, Hologic has further advanced tomosynthesis with faster and lower-dose options including the C-View™ software option for 2D imaging and the Affirm™ tomosynthesis biopsy procedure. Tomosynthesis is going from strength...Read more
Rsna-2013-hologic-to-showcase-its-3d-imaging-portfolio
2013 22 Nov
3D Mammography, Hologic's game-changing breast cancer screening technology, is a major focus at the largest radiology gathering in the world Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women,...Read more
Arab-health-2014-hologic-to-showcase-award-winning-3d-mammography-platform
2014 28 Jan
With an emphasis on improving lives, Hologic is focused on bringing the latest in diagnostic innovations to the fast growing Gulf region Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, will feature...Read more
Three-new-peer-reviewed-publications-further-validate-the-benefits-of-hologic-tomosynthesis
2014 12 Feb
Research supports the use of Hologic's lower dose 3D mammography technology and the continued use of two-views over one in breast cancer screening Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women,...Read more
Ecr2015-hologic-satellite-symposium-screening-with-breast-tomosynthesis-an-emerging-reality
2015 26 Feb
The amount of clinical proof for the efficacy of Tomosynthesis in screening is significantly larger than the proof available in the early days of the transition from analog mammography to FFDM. Results from studies in Europe using Tomosynthesis in population based screening and results from screening with Tomosynthesis in the USA are concordant...Read more
Hologic-enters-into-five-year-secured-credit-agreement
2015 29 May
Initial Proceeds from New $1.5 Billion Term Loan and $1 Billion Revolving Credit Line Used to Refinance Senior Secured Debt PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that the Company has entered into a new, five-year secured credit agreement consisting of a $1.5 billion senior Term Loan and a $1 billion revolving credit facility....Read more
Hologic-to-present-at-upcoming-investor-conferences-1
2015 07 May
BEDFORD, Mass. , May 7, 2015 / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced today that the Company will present at two upcoming investor conferences in May: The Bank of America Merrill Lynch 2015 Healthcare Conference in Las Vegas on Tuesday, May 12 at 1:40 pm Pacific Time (PT). The UBS Global Healthcare Conference in New York...Read more
Hologic-announces-financial-results-for-second-quarter-fiscal-2015-1
2015 29 Apr
- Revenues of $655.5 Million Grow 4.9% on a Reported Basis, 7.2% in Constant Currency - - Company Records GAAP EPS of $0.17, Non-GAAP EPS of $0.41 - - Company Raises Full-Year Revenue and Earnings Guidance - BEDFORD, Mass. , / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced today the Company's financial results for the second...Read more
Hologic-comments-on-important-cervical-cancer-screening-study
2015 16 Apr
BEDFORD, Mass. , / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) today commented on an important cervical cancer screening studyi published on-line this week in Cancer Cytopathology , a peer-reviewed journal of the American Cancer Society. The study, by researchers at Quest Diagnostics and the University of Pittsburgh Medical Center, supports current...Read more
Hologic-to-announce-financial-results-for-the-second-quarter-of-fiscal-2015-on-wednesday-april-29
2015 06 Apr
BEDFORD, Mass. , / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that the Company plans to release its operating results for the second quarter of fiscal 2015 on Wednesday, April 29, 2015 , after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time . Interested participants...Read more
Hologic-delivers-notice-that-holders-of-2-00
2015 01 Apr
BEDFORD, Mass. ,/ PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010 , and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes. ...Read more
Kristin-chenoweth-named-national-celebrity-spokesperson-for-hologic-s-demand-genius
2015 15 Jun
BEDFORD, Mass. ,/ PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that award-winning actress and singer Kristin Chenoweth will serve as spokesperson for a national campaign to generate awareness of Hologic's Genius 3D Mammography exam, a more accurate mammogram that has been clinically proven to reduce callbacks by up to 40 percent and...Read more
Hologic-announces-changes-to-board-of-directors
2015 17 Jun
BEDFORD, Mass. , / PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced that David LaVance has resigned as Chairman of the Company's Board of Directors, and notified the Board that he will not stand for re-election at the 2016 Annual Meeting of Stockholders. Steve MacMillan , Hologic's President and Chief Executive Officer, has been appointed...Read more
Hologic-comments-on-important-cervical-cancer-screening-study-1
2015 16 Jul
Hologic, Inc. (NASDAQ: HOLX) has commented on an important cervical cancer screening studyipublished on-line this week in Cancer Cytopathology , a peer-reviewed journal of the American Cancer Society. The study, by researchers at Quest Diagnostics and the University of Pittsburgh Medical Center, supports current consensus guidelinesii for cervical...Read more
Hologic-s-genius-3d-mammography-continues-to-lead-the-u-s-breast-tomosynthesis-market
2015 29 Sep
Mammography providers say Hologic stands out for technology innovation, high image quality, and C-View™ dose-reduction technology Hologic, Inc. (NASDAQ: HOLX) announced that U.S. mammography providers gave Hologic and Hologic's Genius™ 3D Mammography™ exams top scores in a new study by KLAS Research, Women's Imaging 2015. Are New Technologies Delivering...Read more
Hologic-kicks-off-breast-cancer-awareness-month-by-ringing-the-nasdaq-opening-bell
2015 30 Sep
Chenoweth to Serve as Spokeswoman for National Campaign to Increase Insurance Coverage of Hologic's Genius™ 3D Mammography™ Exam -- Hologic, Inc. (Nasdaq: HOLX) announced that award-winning actress and singer Kristin Chenoweth will join Steve MacMillan , the Company's Chairman, President and Chief Executive Officer, to ring the Nasdaq Opening...Read more
New-modeling-analysis-shows-screening-for-cervical-cancer-with-pap-hpv-together
2015 12 Nov
Co-testing could prevent more cases of invasive cervical cancer and cost the health care system less money over time, study shows Researchers presented a new clinical-economic modeling analysis this week showing that screening for cervical cancer with Pap+HPV Together™ (co-testing) using the Aptima® HPV assay (an mRNA-based HPV test) and the...Read more
Hologic-expands-its-european-virology-portfolio-with-ce-ivd-certified-assay-for-hbv-viral-load
2015 10 Dec
-- Aptima® HBV Quant Assay Joins Tests for HIV-1 and HCV on the Fully Automated Panther Instrument -- Hologic, Inc. has earned CE-IVD certification for its Aptima HBV Quant assay on the fully automated Panther® instrument, the Company has announced. This assay expands the European virology menu available on the Panther system, which previously...Read more
Hologic-s-3d-mammography-bus-takes-center-stage-at-massachusetts-conference-for-women
2015 07 Dec
A high-profile conference for Boston-area women will host Marlborough-based Hologic and its 40-foot 3D MAMMOGRAPHY™ bus, a hands-on display of the latest innovation in breast cancer screening. Hologic’s 3D MAMMOGRAPHY™ bus is a walk-through tour and information center for women to learn about a new kind of mammogram, which clinical studies have...Read more
Hologic-launches-first-fully-automated-sample-to-result-molecular-assay-in-europe
2015 16 Dec
-- The CE-marked Aptima® Mycoplasma genitalium Assay on the Panther® System Identifies a Prevalent, Often Misdiagnosed Sexually Transmitted Infection -- Hologic, Inc. has announced the European launch of the CE-marked Aptima Mycoplasma genitalium assay, adding to the growing menu of molecular tests available on the fully automated Panther system....Read more
Hologic-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference
2015 21 Dec
Hologic, Inc. has announced that the Company will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2016 at 2 p.m. Pacific Time . The presentation will be webcast live and may be accessed through a link on the investors section of Hologic's website at http://investors.hologic.com . The webcast will...Read more
Hologic-applauds-passage-of-federal-measures-that-preserve-access-to-breast-cancer-screening
2015 22 Dec
Hologic, Inc. has expressed support for new federal measures that preserve access to mammography for breast cancer screening and increase incentives for biomedical research and development. These measures were recently passed with bipartisan Congressional support and signed into law by the President. Essential components of the Protect Access to...Read more
Hologic-to-announce-financial-results-for-the-first-quarter-of-fiscal-2016-on-january-27-2016
2016 04 Jan
Hologic, Inc. has announced that the Company plans to release its financial results for the first quarter of fiscal 2016 on Wednesday, January 27, 2016 , after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time . Interested participants may listen to the call by dialing...Read more
Hologic-delivers-notice-that-holders-of-2-00-converts-due-2037-are-eligible-to-convert
2016 05 Jan
Hologic, Inc. has announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes. This conversion right is subject to the terms of...Read more
Hologic-to-webcast-presentations-at-upcoming-investor-conferences
2016 03 Feb
Hologic, Inc. has announced that the Company will present at these upcoming investor conferences: The LEERINK Partners 5 th Annual Global Healthcare Conference in New York, NY on Wednesday, February 10 at 3:05 pm Eastern Time (ET). The RBC Capital Markets 2016 Global Healthcare Conference in New York, NY on Tuesday, FebrRead more